Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neurofibromatosis 2 | 64 | 2024 | 388 | 14.590 |
Why?
|
Neurofibromatoses | 55 | 2024 | 303 | 13.370 |
Why?
|
Neurofibromatosis 1 | 57 | 2024 | 561 | 11.110 |
Why?
|
Neurilemmoma | 50 | 2024 | 522 | 10.760 |
Why?
|
Neuroma, Acoustic | 25 | 2023 | 455 | 5.080 |
Why?
|
Skin Neoplasms | 45 | 2024 | 5863 | 3.660 |
Why?
|
Hearing Loss | 14 | 2023 | 785 | 2.620 |
Why?
|
Neurofibroma | 11 | 2024 | 95 | 2.260 |
Why?
|
Meningeal Neoplasms | 16 | 2024 | 1253 | 1.990 |
Why?
|
Meningioma | 15 | 2024 | 1220 | 1.790 |
Why?
|
Nerve Sheath Neoplasms | 6 | 2020 | 169 | 1.720 |
Why?
|
Neurofibroma, Plexiform | 8 | 2022 | 66 | 1.660 |
Why?
|
Angiogenesis Inhibitors | 12 | 2019 | 2057 | 1.490 |
Why?
|
von Hippel-Lindau Disease | 3 | 2020 | 154 | 1.360 |
Why?
|
Neurofibromin 2 | 14 | 2023 | 271 | 1.350 |
Why?
|
Clinical Trials as Topic | 18 | 2023 | 8052 | 1.100 |
Why?
|
Brain Neoplasms | 21 | 2021 | 9118 | 1.080 |
Why?
|
Organophosphorus Compounds | 2 | 2024 | 211 | 1.020 |
Why?
|
Nervous System Neoplasms | 3 | 2018 | 91 | 0.970 |
Why?
|
Quinazolines | 9 | 2015 | 1373 | 0.970 |
Why?
|
Whole Body Imaging | 8 | 2020 | 284 | 0.900 |
Why?
|
Rare Diseases | 7 | 2022 | 631 | 0.890 |
Why?
|
Quality of Life | 20 | 2024 | 13490 | 0.890 |
Why?
|
Tuberous Sclerosis | 3 | 2020 | 1042 | 0.850 |
Why?
|
Tumor Burden | 9 | 2024 | 1906 | 0.790 |
Why?
|
Chromosomal Proteins, Non-Histone | 4 | 2013 | 724 | 0.780 |
Why?
|
Lymphoma | 6 | 2023 | 1898 | 0.670 |
Why?
|
Maternal Mortality | 2 | 2013 | 310 | 0.660 |
Why?
|
Peripheral Nervous System Neoplasms | 3 | 2017 | 133 | 0.630 |
Why?
|
Mind-Body Therapies | 3 | 2019 | 294 | 0.630 |
Why?
|
Glioblastoma | 12 | 2021 | 3464 | 0.610 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2020 | 249 | 0.600 |
Why?
|
Humans | 197 | 2024 | 768171 | 0.590 |
Why?
|
Antineoplastic Agents | 15 | 2024 | 13677 | 0.590 |
Why?
|
Central Nervous System Neoplasms | 5 | 2023 | 928 | 0.580 |
Why?
|
Spinal Cord Neoplasms | 4 | 2015 | 263 | 0.570 |
Why?
|
Adult | 87 | 2024 | 223646 | 0.550 |
Why?
|
Consensus | 5 | 2023 | 3211 | 0.530 |
Why?
|
Psychotherapy, Group | 2 | 2019 | 417 | 0.530 |
Why?
|
Telemedicine | 6 | 2021 | 3109 | 0.530 |
Why?
|
Young Adult | 40 | 2024 | 60066 | 0.520 |
Why?
|
Oscillometry | 1 | 2016 | 151 | 0.520 |
Why?
|
Pregnancy Complications | 3 | 2015 | 2973 | 0.520 |
Why?
|
Pyrimidines | 5 | 2024 | 3048 | 0.520 |
Why?
|
Pregnancy Outcome | 3 | 2015 | 2972 | 0.490 |
Why?
|
Treatment Outcome | 30 | 2024 | 65379 | 0.490 |
Why?
|
Ependymoma | 3 | 2015 | 328 | 0.470 |
Why?
|
Hearing Tests | 2 | 2019 | 123 | 0.460 |
Why?
|
Magnetic Resonance Imaging | 35 | 2024 | 36741 | 0.460 |
Why?
|
Adolescent | 46 | 2024 | 89169 | 0.450 |
Why?
|
Germ-Line Mutation | 5 | 2020 | 1885 | 0.450 |
Why?
|
Facial Nerve Diseases | 1 | 2013 | 49 | 0.440 |
Why?
|
Spirometry | 1 | 2016 | 929 | 0.420 |
Why?
|
Preimplantation Diagnosis | 1 | 2014 | 143 | 0.410 |
Why?
|
Vascular Endothelial Growth Factor A | 6 | 2017 | 3517 | 0.410 |
Why?
|
Lymphatic Diseases | 1 | 2014 | 319 | 0.400 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2014 | 2055 | 0.400 |
Why?
|
Middle Aged | 68 | 2024 | 223487 | 0.400 |
Why?
|
S100 Proteins | 1 | 2012 | 216 | 0.400 |
Why?
|
Protein Kinase Inhibitors | 11 | 2024 | 5704 | 0.400 |
Why?
|
Male | 90 | 2024 | 364731 | 0.390 |
Why?
|
Osteoarthritis, Knee | 1 | 2022 | 1251 | 0.390 |
Why?
|
Female | 87 | 2024 | 397187 | 0.370 |
Why?
|
Enkephalins | 3 | 2001 | 139 | 0.360 |
Why?
|
Transcription Factors | 7 | 2020 | 12171 | 0.360 |
Why?
|
Genomics | 2 | 2024 | 5926 | 0.360 |
Why?
|
Relaxation Therapy | 3 | 2023 | 181 | 0.350 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2012 | 640 | 0.350 |
Why?
|
TOR Serine-Threonine Kinases | 3 | 2020 | 2062 | 0.350 |
Why?
|
Enkephalin, Methionine | 3 | 2001 | 26 | 0.340 |
Why?
|
Child | 31 | 2024 | 80917 | 0.340 |
Why?
|
DNA-Binding Proteins | 4 | 2013 | 9617 | 0.340 |
Why?
|
Nerve Growth Factors | 1 | 2012 | 564 | 0.340 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2012 | 260 | 0.340 |
Why?
|
Medical Oncology | 3 | 2022 | 2346 | 0.330 |
Why?
|
Affective Symptoms | 1 | 2012 | 418 | 0.330 |
Why?
|
Polysomnography | 1 | 2016 | 1871 | 0.330 |
Why?
|
Genetic Association Studies | 5 | 2020 | 2744 | 0.330 |
Why?
|
Disease Progression | 9 | 2024 | 13668 | 0.320 |
Why?
|
Videoconferencing | 4 | 2019 | 209 | 0.320 |
Why?
|
Neoplasm Recurrence, Local | 10 | 2021 | 9419 | 0.320 |
Why?
|
Cerebrovascular Disorders | 1 | 2015 | 1485 | 0.310 |
Why?
|
Spinal Nerves | 1 | 2009 | 92 | 0.310 |
Why?
|
Follow-Up Studies | 20 | 2023 | 39354 | 0.310 |
Why?
|
Cranial Nerves | 1 | 2009 | 97 | 0.300 |
Why?
|
Multiprotein Complexes | 2 | 2014 | 1110 | 0.300 |
Why?
|
Ambulatory Care | 2 | 2018 | 2783 | 0.300 |
Why?
|
Ethanol | 3 | 2001 | 1331 | 0.300 |
Why?
|
Methotrexate | 3 | 2023 | 1721 | 0.300 |
Why?
|
Herpes Zoster Oticus | 1 | 2007 | 7 | 0.290 |
Why?
|
Ear Neoplasms | 1 | 2008 | 118 | 0.290 |
Why?
|
Obstetric Labor, Premature | 3 | 2015 | 268 | 0.290 |
Why?
|
ras Proteins | 3 | 2019 | 1058 | 0.280 |
Why?
|
Genes, Tumor Suppressor | 2 | 2009 | 1062 | 0.280 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 4 | 2024 | 637 | 0.280 |
Why?
|
Cafe-au-Lait Spots | 2 | 2021 | 20 | 0.270 |
Why?
|
Single-Blind Method | 6 | 2023 | 1587 | 0.260 |
Why?
|
Interleukin-1 | 4 | 2000 | 1252 | 0.260 |
Why?
|
Astrocytoma | 1 | 2010 | 774 | 0.260 |
Why?
|
Population Surveillance | 2 | 2016 | 2596 | 0.260 |
Why?
|
Molecular Targeted Therapy | 3 | 2019 | 2830 | 0.260 |
Why?
|
Research | 1 | 2014 | 1979 | 0.260 |
Why?
|
Resilience, Psychological | 3 | 2020 | 807 | 0.260 |
Why?
|
Attitude to Health | 2 | 2008 | 2025 | 0.260 |
Why?
|
Positron-Emission Tomography | 4 | 2019 | 6669 | 0.260 |
Why?
|
Audiometry, Pure-Tone | 3 | 2012 | 210 | 0.250 |
Why?
|
Hearing Loss, Sensorineural | 2 | 2010 | 783 | 0.250 |
Why?
|
Spinal Neoplasms | 1 | 2012 | 715 | 0.250 |
Why?
|
Nervous System | 1 | 2009 | 544 | 0.250 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2004 | 1375 | 0.250 |
Why?
|
Pain Measurement | 4 | 2022 | 3583 | 0.240 |
Why?
|
Viral Envelope Proteins | 3 | 1996 | 640 | 0.240 |
Why?
|
Methionine | 1 | 2007 | 573 | 0.240 |
Why?
|
Brain Diseases | 1 | 2014 | 1554 | 0.240 |
Why?
|
Dose-Response Relationship, Drug | 6 | 2022 | 10763 | 0.240 |
Why?
|
Mitogen-Activated Protein Kinases | 3 | 2020 | 1246 | 0.240 |
Why?
|
Antibodies, Monoclonal | 3 | 2010 | 9262 | 0.240 |
Why?
|
Genes, Neurofibromatosis 1 | 3 | 2021 | 74 | 0.240 |
Why?
|
Rabies Vaccines | 2 | 1996 | 29 | 0.230 |
Why?
|
Cranial Nerve Neoplasms | 1 | 2005 | 131 | 0.230 |
Why?
|
Substance Withdrawal Syndrome | 2 | 2001 | 628 | 0.230 |
Why?
|
Hypesthesia | 1 | 2005 | 106 | 0.230 |
Why?
|
Aged | 36 | 2022 | 171502 | 0.230 |
Why?
|
Blood-Brain Barrier | 4 | 2000 | 1035 | 0.230 |
Why?
|
Prospective Studies | 17 | 2023 | 54924 | 0.230 |
Why?
|
Cochlear Implantation | 1 | 2008 | 317 | 0.220 |
Why?
|
Hearing Disorders | 1 | 2024 | 126 | 0.220 |
Why?
|
Genes, Neurofibromatosis 2 | 3 | 2008 | 122 | 0.220 |
Why?
|
Retrospective Studies | 22 | 2023 | 81760 | 0.220 |
Why?
|
Seminoma | 1 | 2005 | 136 | 0.220 |
Why?
|
Disease Models, Animal | 6 | 2021 | 18349 | 0.220 |
Why?
|
Paraneoplastic Syndromes | 1 | 2005 | 154 | 0.210 |
Why?
|
Radiation Injuries | 1 | 2010 | 1198 | 0.210 |
Why?
|
Prognosis | 14 | 2024 | 30009 | 0.210 |
Why?
|
Patient Selection | 2 | 2021 | 4260 | 0.210 |
Why?
|
Hearing | 4 | 2022 | 504 | 0.210 |
Why?
|
Lymph Nodes | 1 | 2014 | 3474 | 0.200 |
Why?
|
Survival Rate | 7 | 2019 | 12840 | 0.200 |
Why?
|
Stress, Psychological | 2 | 2015 | 4530 | 0.200 |
Why?
|
Demyelinating Diseases | 1 | 2005 | 358 | 0.200 |
Why?
|
Hamartoma | 1 | 2024 | 236 | 0.190 |
Why?
|
Vaccines, Synthetic | 2 | 1996 | 622 | 0.190 |
Why?
|
Drug Administration Schedule | 3 | 2016 | 4861 | 0.190 |
Why?
|
MSH Release-Inhibiting Hormone | 1 | 2001 | 9 | 0.190 |
Why?
|
Connective Tissue Diseases | 2 | 2021 | 285 | 0.190 |
Why?
|
Neuroma | 1 | 2023 | 138 | 0.190 |
Why?
|
Arthrogryposis | 1 | 2022 | 69 | 0.190 |
Why?
|
Anxiety | 1 | 2016 | 4672 | 0.180 |
Why?
|
Fibroblast Growth Factor 7 | 1 | 2021 | 59 | 0.180 |
Why?
|
Diphenylamine | 1 | 2021 | 49 | 0.180 |
Why?
|
Glycoproteins | 3 | 1996 | 2202 | 0.180 |
Why?
|
Blood-Testis Barrier | 1 | 2000 | 12 | 0.180 |
Why?
|
Isometric Contraction | 1 | 2021 | 149 | 0.180 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2014 | 1536 | 0.180 |
Why?
|
Genetic Diseases, Inborn | 2 | 2016 | 606 | 0.180 |
Why?
|
Pseudarthrosis | 1 | 2021 | 54 | 0.180 |
Why?
|
Health Services Accessibility | 1 | 2018 | 5520 | 0.180 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2004 | 646 | 0.180 |
Why?
|
Tinnitus | 1 | 2023 | 197 | 0.170 |
Why?
|
Cesarean Section | 3 | 2015 | 1425 | 0.170 |
Why?
|
Benzamides | 3 | 2021 | 1379 | 0.170 |
Why?
|
Antigens, Viral | 2 | 1996 | 995 | 0.170 |
Why?
|
Central Nervous System Depressants | 1 | 2001 | 163 | 0.170 |
Why?
|
Mutation, Missense | 3 | 2017 | 2592 | 0.170 |
Why?
|
Neuregulin-1 | 1 | 2020 | 136 | 0.170 |
Why?
|
Hydrazines | 1 | 2021 | 223 | 0.170 |
Why?
|
Autocrine Communication | 1 | 2020 | 168 | 0.170 |
Why?
|
Protein Precursors | 3 | 2001 | 1135 | 0.170 |
Why?
|
Receptor, erbB-3 | 1 | 2020 | 142 | 0.170 |
Why?
|
Cerebellar Neoplasms | 1 | 2005 | 591 | 0.170 |
Why?
|
Neurotoxicity Syndromes | 1 | 2023 | 302 | 0.170 |
Why?
|
Muscle Weakness | 2 | 2021 | 412 | 0.160 |
Why?
|
Neovascularization, Pathologic | 4 | 2017 | 2631 | 0.160 |
Why?
|
Radiosurgery | 3 | 2022 | 1330 | 0.160 |
Why?
|
Hospitalization | 4 | 2015 | 10840 | 0.160 |
Why?
|
Depression | 2 | 2016 | 8230 | 0.160 |
Why?
|
Medicine, Traditional | 1 | 1999 | 89 | 0.160 |
Why?
|
Bone Morphogenetic Protein 2 | 1 | 2021 | 344 | 0.160 |
Why?
|
Administration, Oral | 2 | 2024 | 4034 | 0.160 |
Why?
|
Cerebellopontine Angle | 1 | 2019 | 53 | 0.160 |
Why?
|
Imaging, Three-Dimensional | 2 | 2009 | 4064 | 0.150 |
Why?
|
Receptors, Eph Family | 1 | 2018 | 45 | 0.150 |
Why?
|
Neurology | 2 | 2021 | 786 | 0.150 |
Why?
|
International Classification of Diseases | 2 | 2015 | 937 | 0.150 |
Why?
|
Testicular Neoplasms | 1 | 2005 | 806 | 0.150 |
Why?
|
Fetal Growth Retardation | 2 | 2013 | 592 | 0.150 |
Why?
|
Receptor, IGF Type 1 | 1 | 2020 | 384 | 0.150 |
Why?
|
Pain | 6 | 2023 | 5099 | 0.150 |
Why?
|
Brain Death | 1 | 2001 | 359 | 0.150 |
Why?
|
Spinal Injuries | 1 | 2001 | 300 | 0.150 |
Why?
|
Bone and Bones | 1 | 2009 | 2590 | 0.150 |
Why?
|
Organizations, Nonprofit | 1 | 2018 | 105 | 0.150 |
Why?
|
Immunohistochemistry | 5 | 2015 | 11095 | 0.150 |
Why?
|
Anilides | 1 | 2021 | 413 | 0.150 |
Why?
|
Salvage Therapy | 1 | 2004 | 1273 | 0.150 |
Why?
|
Image Interpretation, Computer-Assisted | 2 | 2017 | 3390 | 0.140 |
Why?
|
Adjuvants, Immunologic | 1 | 2003 | 999 | 0.140 |
Why?
|
Cohort Studies | 10 | 2020 | 41753 | 0.140 |
Why?
|
DNA Methylation | 3 | 2024 | 4428 | 0.140 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2003 | 716 | 0.140 |
Why?
|
Muscle Strength | 1 | 2021 | 640 | 0.140 |
Why?
|
Animals | 29 | 2023 | 169285 | 0.130 |
Why?
|
Avipoxvirus | 1 | 1996 | 4 | 0.130 |
Why?
|
Seizures | 3 | 2001 | 2998 | 0.130 |
Why?
|
Tumor Microenvironment | 4 | 2021 | 3948 | 0.130 |
Why?
|
Patient Satisfaction | 2 | 2021 | 3490 | 0.130 |
Why?
|
Neurofibromin 1 | 1 | 2017 | 190 | 0.130 |
Why?
|
Triazoles | 1 | 2021 | 904 | 0.130 |
Why?
|
Attitude | 1 | 2021 | 772 | 0.130 |
Why?
|
Boston | 4 | 2015 | 9374 | 0.130 |
Why?
|
Codon | 1 | 2017 | 599 | 0.130 |
Why?
|
Capillary Permeability | 1 | 2019 | 772 | 0.130 |
Why?
|
Dacarbazine | 3 | 2013 | 552 | 0.130 |
Why?
|
Anesthesia, Local | 1 | 1998 | 279 | 0.130 |
Why?
|
Cytomegalovirus | 2 | 1990 | 753 | 0.130 |
Why?
|
Immunotherapy, Adoptive | 2 | 2023 | 1512 | 0.120 |
Why?
|
Neuropeptides | 2 | 2001 | 951 | 0.120 |
Why?
|
Analgesics | 1 | 2022 | 1071 | 0.120 |
Why?
|
Disease-Free Survival | 6 | 2015 | 6847 | 0.120 |
Why?
|
Cervical Vertebrae | 1 | 2001 | 979 | 0.120 |
Why?
|
Health Literacy | 2 | 2017 | 466 | 0.120 |
Why?
|
Skin | 1 | 2009 | 4505 | 0.120 |
Why?
|
Deafness | 1 | 2019 | 460 | 0.120 |
Why?
|
Attitude of Health Personnel | 1 | 2008 | 3929 | 0.120 |
Why?
|
Pyridines | 2 | 2021 | 2894 | 0.120 |
Why?
|
Relaxation | 1 | 2014 | 51 | 0.120 |
Why?
|
Pre-Eclampsia | 2 | 2015 | 1255 | 0.120 |
Why?
|
Compassionate Use Trials | 1 | 2014 | 50 | 0.110 |
Why?
|
Mice | 21 | 2023 | 82049 | 0.110 |
Why?
|
Diagnostic Errors | 1 | 2001 | 1281 | 0.110 |
Why?
|
Feasibility Studies | 4 | 2019 | 5315 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2018 | 564 | 0.110 |
Why?
|
Spinal Cord Injuries | 1 | 2001 | 928 | 0.110 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 3 | 2015 | 548 | 0.110 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2018 | 614 | 0.110 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2015 | 5432 | 0.110 |
Why?
|
Logistic Models | 3 | 2015 | 13290 | 0.110 |
Why?
|
Albumins | 1 | 1996 | 577 | 0.110 |
Why?
|
Posterior Leukoencephalopathy Syndrome | 1 | 2014 | 50 | 0.110 |
Why?
|
Genetic Testing | 3 | 2022 | 3591 | 0.110 |
Why?
|
Sequence Analysis, RNA | 1 | 2021 | 2040 | 0.110 |
Why?
|
Automobile Driving | 1 | 2018 | 442 | 0.110 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2022 | 2568 | 0.100 |
Why?
|
Transforming Growth Factor beta | 1 | 2021 | 2004 | 0.100 |
Why?
|
Turner Syndrome | 1 | 2014 | 130 | 0.100 |
Why?
|
Fellowships and Scholarships | 1 | 2021 | 1135 | 0.100 |
Why?
|
Patient Acceptance of Health Care | 3 | 2019 | 3231 | 0.100 |
Why?
|
Communication | 4 | 2021 | 3905 | 0.100 |
Why?
|
Somatostatin | 1 | 2014 | 458 | 0.100 |
Why?
|
Laryngeal Diseases | 1 | 2016 | 248 | 0.100 |
Why?
|
Risk Assessment | 5 | 2015 | 24318 | 0.100 |
Why?
|
Age Distribution | 1 | 2018 | 2873 | 0.100 |
Why?
|
Immediate-Early Proteins | 1 | 2015 | 444 | 0.100 |
Why?
|
Poxviridae | 1 | 1992 | 37 | 0.100 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 2271 | 0.100 |
Why?
|
Travel | 1 | 2018 | 805 | 0.100 |
Why?
|
Diagnostic Imaging | 2 | 2019 | 3533 | 0.100 |
Why?
|
Muscle, Skeletal | 2 | 2021 | 4978 | 0.100 |
Why?
|
Ambulatory Care Facilities | 1 | 2018 | 939 | 0.100 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2012 | 95 | 0.100 |
Why?
|
Rabies | 1 | 1992 | 56 | 0.100 |
Why?
|
Membrane Transport Proteins | 1 | 1998 | 1037 | 0.100 |
Why?
|
Infratentorial Neoplasms | 1 | 2012 | 99 | 0.100 |
Why?
|
Pregnancy | 4 | 2015 | 30255 | 0.100 |
Why?
|
Choroid | 2 | 2024 | 364 | 0.100 |
Why?
|
Principal Component Analysis | 1 | 2015 | 948 | 0.100 |
Why?
|
Review Literature as Topic | 1 | 2013 | 297 | 0.090 |
Why?
|
Radiography | 2 | 2014 | 6986 | 0.090 |
Why?
|
Arachnoid | 2 | 2009 | 50 | 0.090 |
Why?
|
Cell Line, Tumor | 8 | 2021 | 17142 | 0.090 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 10397 | 0.090 |
Why?
|
Adaptation, Psychological | 2 | 2020 | 2663 | 0.090 |
Why?
|
Urban Population | 1 | 1999 | 2046 | 0.090 |
Why?
|
Emotions | 1 | 2023 | 2767 | 0.090 |
Why?
|
Live Birth | 1 | 2014 | 516 | 0.090 |
Why?
|
Proteinuria | 1 | 2014 | 611 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2018 | 3556 | 0.090 |
Why?
|
Anesthetics, Local | 1 | 1998 | 1005 | 0.090 |
Why?
|
Morpholines | 3 | 2020 | 584 | 0.090 |
Why?
|
Air Microbiology | 1 | 1991 | 95 | 0.090 |
Why?
|
Loneliness | 1 | 2013 | 211 | 0.090 |
Why?
|
Orthopedic Procedures | 1 | 2021 | 1279 | 0.090 |
Why?
|
Biological Specimen Banks | 1 | 2016 | 788 | 0.090 |
Why?
|
Genes, tat | 1 | 1990 | 15 | 0.090 |
Why?
|
Physicians | 1 | 2008 | 4598 | 0.090 |
Why?
|
Biopsy, Needle | 1 | 2015 | 1623 | 0.090 |
Why?
|
United States | 7 | 2022 | 73039 | 0.090 |
Why?
|
Cyclin D1 | 1 | 2012 | 453 | 0.090 |
Why?
|
Psychotherapy | 1 | 2019 | 1654 | 0.090 |
Why?
|
Family | 3 | 2016 | 3209 | 0.090 |
Why?
|
RNA Stability | 1 | 2012 | 320 | 0.090 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2015 | 1791 | 0.090 |
Why?
|
3' Untranslated Regions | 1 | 2012 | 515 | 0.090 |
Why?
|
Aged, 80 and over | 10 | 2015 | 59626 | 0.090 |
Why?
|
Social Adjustment | 1 | 2012 | 635 | 0.090 |
Why?
|
Cerebrospinal Fluid Shunts | 1 | 1991 | 197 | 0.090 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2018 | 8648 | 0.080 |
Why?
|
Combined Modality Therapy | 4 | 2010 | 8542 | 0.080 |
Why?
|
Paranasal Sinuses | 1 | 2012 | 267 | 0.080 |
Why?
|
Self Report | 2 | 2018 | 3773 | 0.080 |
Why?
|
Virus Integration | 1 | 1992 | 307 | 0.080 |
Why?
|
Neurosurgical Procedures | 2 | 2015 | 2077 | 0.080 |
Why?
|
Congresses as Topic | 1 | 2014 | 812 | 0.080 |
Why?
|
Neuropilin-2 | 1 | 2009 | 55 | 0.080 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 2 | 2010 | 662 | 0.080 |
Why?
|
Image Processing, Computer-Assisted | 5 | 2022 | 9016 | 0.080 |
Why?
|
Neuropilin-1 | 1 | 2009 | 91 | 0.080 |
Why?
|
Nursing Methodology Research | 1 | 2008 | 64 | 0.080 |
Why?
|
DNA, Complementary | 1 | 2012 | 1989 | 0.080 |
Why?
|
Genes, Viral | 1 | 1990 | 655 | 0.080 |
Why?
|
Cell Proliferation | 5 | 2023 | 10478 | 0.080 |
Why?
|
Snake Venoms | 1 | 2008 | 40 | 0.080 |
Why?
|
RNA, Messenger | 3 | 2001 | 12801 | 0.080 |
Why?
|
Injections, Intraventricular | 3 | 2019 | 227 | 0.080 |
Why?
|
Delphi Technique | 2 | 2024 | 890 | 0.080 |
Why?
|
Residence Characteristics | 1 | 2018 | 2118 | 0.080 |
Why?
|
Cerebrospinal Fluid | 2 | 2007 | 540 | 0.080 |
Why?
|
Body Image | 1 | 2013 | 646 | 0.080 |
Why?
|
Perception | 1 | 2015 | 1209 | 0.080 |
Why?
|
Videotape Recording | 1 | 2009 | 335 | 0.080 |
Why?
|
Double-Blind Method | 1 | 2022 | 12466 | 0.070 |
Why?
|
Risk Factors | 6 | 2015 | 74944 | 0.070 |
Why?
|
Facial Paralysis | 1 | 2012 | 346 | 0.070 |
Why?
|
Pyrroles | 1 | 2014 | 1124 | 0.070 |
Why?
|
MAP Kinase Signaling System | 1 | 2015 | 1495 | 0.070 |
Why?
|
Geriatric Assessment | 1 | 2015 | 1422 | 0.070 |
Why?
|
Signal Transduction | 8 | 2020 | 23648 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2023 | 4058 | 0.070 |
Why?
|
RNA Splicing | 1 | 2012 | 905 | 0.070 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2021 | 3612 | 0.070 |
Why?
|
Phthalazines | 1 | 2010 | 397 | 0.070 |
Why?
|
Peripheral Nervous System | 1 | 2009 | 151 | 0.070 |
Why?
|
Joint Diseases | 1 | 2011 | 461 | 0.070 |
Why?
|
Lung Neoplasms | 2 | 2015 | 13586 | 0.070 |
Why?
|
Colorectal Neoplasms | 1 | 2007 | 6975 | 0.070 |
Why?
|
Intelligence | 1 | 2012 | 926 | 0.070 |
Why?
|
Lymphoma, B-Cell | 1 | 2014 | 945 | 0.070 |
Why?
|
Self Concept | 1 | 2013 | 1043 | 0.070 |
Why?
|
Nurse's Role | 1 | 2008 | 188 | 0.070 |
Why?
|
Mouth Neoplasms | 1 | 2012 | 597 | 0.070 |
Why?
|
Protons | 2 | 2023 | 1113 | 0.070 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2013 | 529 | 0.070 |
Why?
|
Neoplasm Proteins | 2 | 2017 | 3604 | 0.070 |
Why?
|
Epigenesis, Genetic | 1 | 2020 | 3833 | 0.070 |
Why?
|
Mice, Inbred Strains | 2 | 2001 | 1769 | 0.070 |
Why?
|
Radiotherapy | 3 | 2018 | 1502 | 0.070 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2018 | 2815 | 0.070 |
Why?
|
Carbon Isotopes | 1 | 2007 | 458 | 0.070 |
Why?
|
Lyme Neuroborreliosis | 1 | 2007 | 50 | 0.070 |
Why?
|
Neoplasm Staging | 3 | 2015 | 11244 | 0.070 |
Why?
|
Li-Fraumeni Syndrome | 1 | 2007 | 117 | 0.070 |
Why?
|
Phenotype | 5 | 2020 | 16726 | 0.070 |
Why?
|
Auditory Threshold | 1 | 2008 | 369 | 0.070 |
Why?
|
Lung | 2 | 2016 | 10101 | 0.070 |
Why?
|
Simian immunodeficiency virus | 1 | 1992 | 814 | 0.070 |
Why?
|
Peptides, Cyclic | 1 | 2008 | 391 | 0.070 |
Why?
|
Cooperative Behavior | 1 | 2013 | 1514 | 0.070 |
Why?
|
Mutation | 5 | 2016 | 30237 | 0.070 |
Why?
|
Necrosis | 1 | 2010 | 1616 | 0.070 |
Why?
|
Neoplasms | 3 | 2022 | 22371 | 0.070 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2007 | 418 | 0.070 |
Why?
|
Indoles | 1 | 2014 | 1836 | 0.070 |
Why?
|
Microsatellite Repeats | 1 | 2008 | 785 | 0.060 |
Why?
|
Genetics, Medical | 1 | 2008 | 334 | 0.060 |
Why?
|
Autopsy | 2 | 2024 | 1011 | 0.060 |
Why?
|
Infant, Newborn | 5 | 2014 | 26421 | 0.060 |
Why?
|
Speech Perception | 1 | 2010 | 510 | 0.060 |
Why?
|
Vestibular Diseases | 1 | 2008 | 232 | 0.060 |
Why?
|
Borrelia burgdorferi | 1 | 2007 | 183 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 3 | 2020 | 18065 | 0.060 |
Why?
|
Tumor Cells, Cultured | 4 | 2018 | 6124 | 0.060 |
Why?
|
Ear, Inner | 1 | 2009 | 426 | 0.060 |
Why?
|
Operating Rooms | 1 | 1991 | 790 | 0.060 |
Why?
|
Maximum Tolerated Dose | 3 | 2015 | 899 | 0.060 |
Why?
|
Delivery, Obstetric | 1 | 2012 | 954 | 0.060 |
Why?
|
Blindness | 1 | 2009 | 587 | 0.060 |
Why?
|
Eye | 1 | 2009 | 712 | 0.060 |
Why?
|
Hydrocephalus | 1 | 1991 | 768 | 0.060 |
Why?
|
Scoliosis | 1 | 2011 | 793 | 0.060 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5367 | 0.060 |
Why?
|
Paralysis | 3 | 2012 | 250 | 0.060 |
Why?
|
Stereotaxic Techniques | 2 | 2019 | 553 | 0.060 |
Why?
|
Brain | 7 | 2021 | 27362 | 0.060 |
Why?
|
Heart Neoplasms | 1 | 2007 | 374 | 0.060 |
Why?
|
Deoxycholic Acid | 1 | 2023 | 54 | 0.060 |
Why?
|
Molecular Biology | 1 | 2007 | 573 | 0.060 |
Why?
|
Gene Dosage | 1 | 2008 | 1219 | 0.060 |
Why?
|
Autistic Disorder | 2 | 2012 | 1240 | 0.060 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2014 | 1437 | 0.050 |
Why?
|
Cytomegalovirus Infections | 1 | 1990 | 837 | 0.050 |
Why?
|
Regression Analysis | 1 | 2013 | 6340 | 0.050 |
Why?
|
Sexual Behavior | 1 | 2013 | 2197 | 0.050 |
Why?
|
Biological Transport | 3 | 1997 | 2085 | 0.050 |
Why?
|
Research Design | 3 | 2024 | 6209 | 0.050 |
Why?
|
Vertigo | 1 | 2005 | 205 | 0.050 |
Why?
|
Software | 2 | 2017 | 4480 | 0.050 |
Why?
|
Sciatic Nerve | 2 | 2017 | 628 | 0.050 |
Why?
|
Forecasting | 1 | 2012 | 2945 | 0.050 |
Why?
|
Haplotypes | 1 | 2009 | 2722 | 0.050 |
Why?
|
DNA Modification Methylases | 2 | 2013 | 208 | 0.050 |
Why?
|
Ataxia | 1 | 2005 | 307 | 0.050 |
Why?
|
Louisiana | 2 | 1999 | 104 | 0.050 |
Why?
|
Brain Edema | 1 | 2007 | 601 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2019 | 11878 | 0.050 |
Why?
|
Advance Care Planning | 1 | 2009 | 698 | 0.050 |
Why?
|
Cross Infection | 1 | 1991 | 1425 | 0.050 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2023 | 276 | 0.050 |
Why?
|
Administration, Topical | 1 | 2024 | 704 | 0.050 |
Why?
|
Surgical Wound Infection | 1 | 1991 | 1546 | 0.050 |
Why?
|
Oxygen | 1 | 2013 | 4270 | 0.050 |
Why?
|
RNA, Small Interfering | 2 | 2009 | 3428 | 0.050 |
Why?
|
Cranial Irradiation | 1 | 2004 | 393 | 0.050 |
Why?
|
Severity of Illness Index | 2 | 2010 | 15949 | 0.050 |
Why?
|
Muscle Strength Dynamometer | 1 | 2021 | 41 | 0.050 |
Why?
|
Digoxigenin | 1 | 2001 | 26 | 0.050 |
Why?
|
DNA Repair Enzymes | 2 | 2013 | 343 | 0.050 |
Why?
|
Piperidines | 1 | 2010 | 1667 | 0.050 |
Why?
|
Chemoprevention | 1 | 2023 | 327 | 0.050 |
Why?
|
Alleles | 1 | 2012 | 6894 | 0.050 |
Why?
|
Syndrome | 1 | 2007 | 3273 | 0.050 |
Why?
|
Diagnosis, Differential | 7 | 2014 | 13013 | 0.050 |
Why?
|
Child, Preschool | 6 | 2016 | 42669 | 0.050 |
Why?
|
Sciatic Neuropathy | 1 | 2021 | 76 | 0.050 |
Why?
|
Receptor, EphA2 | 1 | 2020 | 41 | 0.050 |
Why?
|
Nerve Regeneration | 2 | 2017 | 797 | 0.040 |
Why?
|
Age Factors | 2 | 2012 | 18415 | 0.040 |
Why?
|
Health Services Needs and Demand | 1 | 2008 | 1406 | 0.040 |
Why?
|
Pandemics | 1 | 2021 | 8747 | 0.040 |
Why?
|
Case-Control Studies | 2 | 2015 | 22290 | 0.040 |
Why?
|
Sleep | 1 | 2016 | 4818 | 0.040 |
Why?
|
Aluminum | 1 | 2001 | 150 | 0.040 |
Why?
|
Radioimmunoassay | 1 | 2001 | 863 | 0.040 |
Why?
|
Central Nervous System | 2 | 2023 | 1346 | 0.040 |
Why?
|
Mice, Nude | 2 | 2021 | 3623 | 0.040 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2021 | 1628 | 0.040 |
Why?
|
Polymerase Chain Reaction | 3 | 2015 | 6082 | 0.040 |
Why?
|
Immunoenzyme Techniques | 2 | 2013 | 1703 | 0.040 |
Why?
|
Evidence-Based Medicine | 1 | 2012 | 3706 | 0.040 |
Why?
|
Half-Life | 1 | 2001 | 651 | 0.040 |
Why?
|
Benzoxazoles | 1 | 2020 | 92 | 0.040 |
Why?
|
Rodentia | 1 | 2021 | 262 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 2 | 2015 | 560 | 0.040 |
Why?
|
Losartan | 1 | 2021 | 262 | 0.040 |
Why?
|
Glasgow Coma Scale | 1 | 2001 | 574 | 0.040 |
Why?
|
Cranial Nerve Diseases | 2 | 2012 | 111 | 0.040 |
Why?
|
Mice, Inbred ICR | 2 | 1997 | 363 | 0.040 |
Why?
|
Immunoblotting | 2 | 2015 | 1648 | 0.040 |
Why?
|
Neutralization Tests | 2 | 1992 | 739 | 0.040 |
Why?
|
Chemotherapy, Cancer, Regional Perfusion | 1 | 2019 | 94 | 0.040 |
Why?
|
Antigens, CD19 | 1 | 2022 | 446 | 0.040 |
Why?
|
Adaptor Proteins, Vesicular Transport | 1 | 2020 | 301 | 0.040 |
Why?
|
Sirolimus | 2 | 2020 | 1540 | 0.040 |
Why?
|
Triazines | 1 | 2020 | 311 | 0.040 |
Why?
|
Motivation | 1 | 2008 | 2020 | 0.040 |
Why?
|
Face | 1 | 2005 | 1031 | 0.040 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2014 | 3729 | 0.040 |
Why?
|
Remission Induction | 1 | 2004 | 2410 | 0.040 |
Why?
|
Chlorofluorocarbons | 1 | 1998 | 12 | 0.040 |
Why?
|
Transfection | 3 | 2009 | 5756 | 0.040 |
Why?
|
Injections, Intravenous | 3 | 1996 | 1379 | 0.040 |
Why?
|
Prilocaine | 1 | 1998 | 21 | 0.040 |
Why?
|
Atmosphere | 1 | 1998 | 32 | 0.040 |
Why?
|
Ointments | 1 | 1998 | 58 | 0.040 |
Why?
|
Macrophages | 1 | 2013 | 5802 | 0.040 |
Why?
|
Photography | 1 | 2021 | 537 | 0.040 |
Why?
|
Sex Factors | 1 | 2012 | 10632 | 0.040 |
Why?
|
Podiatry | 1 | 1998 | 28 | 0.040 |
Why?
|
Poverty Areas | 1 | 1999 | 268 | 0.040 |
Why?
|
Gene Fusion | 1 | 2020 | 356 | 0.040 |
Why?
|
Cicatrix | 1 | 2023 | 798 | 0.040 |
Why?
|
Terminal Care | 1 | 2009 | 1770 | 0.040 |
Why?
|
Mice, Mutant Strains | 1 | 2021 | 1754 | 0.040 |
Why?
|
Radiopharmaceuticals | 1 | 2007 | 2735 | 0.040 |
Why?
|
Herpes Simplex | 2 | 1991 | 470 | 0.040 |
Why?
|
Sample Size | 1 | 2021 | 846 | 0.040 |
Why?
|
Brain Chemistry | 1 | 2001 | 958 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2020 | 2459 | 0.040 |
Why?
|
Sequence Analysis, DNA | 1 | 2008 | 4786 | 0.040 |
Why?
|
Genotype | 2 | 2023 | 13045 | 0.040 |
Why?
|
Disease Management | 2 | 2019 | 2535 | 0.030 |
Why?
|
Luciferases | 1 | 2019 | 713 | 0.030 |
Why?
|
Epilepsy | 1 | 2012 | 3326 | 0.030 |
Why?
|
Vulnerable Populations | 1 | 2022 | 718 | 0.030 |
Why?
|
Median Eminence | 1 | 1996 | 28 | 0.030 |
Why?
|
Time Factors | 3 | 2021 | 40220 | 0.030 |
Why?
|
Pyridazines | 1 | 2018 | 203 | 0.030 |
Why?
|
Reproducibility of Results | 2 | 2021 | 20225 | 0.030 |
Why?
|
Sarcoma | 1 | 2007 | 1806 | 0.030 |
Why?
|
Folic Acid | 1 | 2023 | 1337 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2014 | 2521 | 0.030 |
Why?
|
Research Personnel | 1 | 2021 | 589 | 0.030 |
Why?
|
Species Specificity | 1 | 2000 | 2415 | 0.030 |
Why?
|
Cerebral Hemorrhage | 1 | 2007 | 2654 | 0.030 |
Why?
|
Osmolar Concentration | 1 | 1997 | 657 | 0.030 |
Why?
|
Capital Financing | 1 | 2016 | 58 | 0.030 |
Why?
|
Rotarod Performance Test | 1 | 2015 | 63 | 0.030 |
Why?
|
Trust | 1 | 2020 | 532 | 0.030 |
Why?
|
Organ Culture Techniques | 1 | 2018 | 796 | 0.030 |
Why?
|
Fatal Outcome | 2 | 2012 | 1836 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2008 | 14729 | 0.030 |
Why?
|
Bone Morphogenetic Proteins | 1 | 2021 | 846 | 0.030 |
Why?
|
Pineal Gland | 1 | 1996 | 158 | 0.030 |
Why?
|
Flow Cytometry | 3 | 2013 | 5902 | 0.030 |
Why?
|
Vestibular Nerve | 1 | 2015 | 101 | 0.030 |
Why?
|
Cell Hypoxia | 1 | 2017 | 662 | 0.030 |
Why?
|
Iodine Radioisotopes | 2 | 1996 | 1034 | 0.030 |
Why?
|
Genes, Reporter | 1 | 2019 | 1524 | 0.030 |
Why?
|
Tibia | 1 | 2021 | 1076 | 0.030 |
Why?
|
Recombinant Proteins | 3 | 2021 | 6512 | 0.030 |
Why?
|
Injections | 1 | 1998 | 841 | 0.030 |
Why?
|
Lidocaine | 1 | 1998 | 546 | 0.030 |
Why?
|
Glioma | 1 | 2009 | 3503 | 0.030 |
Why?
|
Cerebral Ventricle Neoplasms | 1 | 2014 | 43 | 0.030 |
Why?
|
Systems Biology | 1 | 2018 | 482 | 0.030 |
Why?
|
Patients | 1 | 2021 | 908 | 0.030 |
Why?
|
Receptors, Cytokine | 1 | 1995 | 258 | 0.030 |
Why?
|
Ozone | 1 | 1998 | 496 | 0.030 |
Why?
|
Factor Analysis, Statistical | 1 | 2017 | 1001 | 0.030 |
Why?
|
Receptors, Interleukin-1 | 1 | 1995 | 260 | 0.030 |
Why?
|
DNA, Viral | 2 | 1992 | 2204 | 0.030 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2019 | 620 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2018 | 1837 | 0.030 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2008 | 4055 | 0.030 |
Why?
|
Hypertension | 1 | 2014 | 8616 | 0.030 |
Why?
|
Receptors, Somatostatin | 1 | 2014 | 138 | 0.030 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2015 | 876 | 0.030 |
Why?
|
Pilot Projects | 2 | 2019 | 8741 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 4 | 2014 | 20762 | 0.030 |
Why?
|
Antigens, CD | 2 | 2013 | 4035 | 0.030 |
Why?
|
Pediatrics | 1 | 2008 | 3629 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 3814 | 0.030 |
Why?
|
Lateral Ventricles | 1 | 2014 | 142 | 0.030 |
Why?
|
Radiation Tolerance | 1 | 2015 | 476 | 0.030 |
Why?
|
Mice, SCID | 1 | 2018 | 2627 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 2 | 2013 | 2810 | 0.030 |
Why?
|
Demography | 1 | 2017 | 1641 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2014 | 6525 | 0.030 |
Why?
|
Immunization | 1 | 1997 | 1219 | 0.030 |
Why?
|
Canaries | 1 | 1992 | 6 | 0.030 |
Why?
|
Antibodies, Viral | 2 | 1996 | 3214 | 0.030 |
Why?
|
Muscular Atrophy | 1 | 2015 | 335 | 0.030 |
Why?
|
Quinolines | 1 | 2018 | 772 | 0.030 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 1995 | 588 | 0.030 |
Why?
|
Hypothermia, Induced | 1 | 1998 | 754 | 0.030 |
Why?
|
MutS Homolog 2 Protein | 1 | 2013 | 200 | 0.030 |
Why?
|
HIV-1 | 1 | 1990 | 6963 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2019 | 1793 | 0.020 |
Why?
|
Community Health Services | 1 | 1997 | 659 | 0.020 |
Why?
|
Patient Participation | 1 | 2021 | 1447 | 0.020 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2021 | 2433 | 0.020 |
Why?
|
Minority Groups | 1 | 1999 | 1216 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2023 | 3858 | 0.020 |
Why?
|
Tissue Transplantation | 1 | 2012 | 128 | 0.020 |
Why?
|
Skull Neoplasms | 1 | 2012 | 173 | 0.020 |
Why?
|
Edema | 1 | 2015 | 765 | 0.020 |
Why?
|
Surgical Equipment | 1 | 1991 | 57 | 0.020 |
Why?
|
Vincristine | 1 | 2014 | 1040 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2016 | 1737 | 0.020 |
Why?
|
User-Computer Interface | 1 | 2017 | 1407 | 0.020 |
Why?
|
Colony Count, Microbial | 1 | 1991 | 328 | 0.020 |
Why?
|
Heterozygote | 1 | 2017 | 2798 | 0.020 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 696 | 0.020 |
Why?
|
Thorax | 1 | 2014 | 557 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2015 | 1606 | 0.020 |
Why?
|
Educational Measurement | 1 | 2017 | 1260 | 0.020 |
Why?
|
Bone Density | 1 | 2023 | 3573 | 0.020 |
Why?
|
Drug Discovery | 1 | 2018 | 1068 | 0.020 |
Why?
|
Peritoneum | 1 | 1991 | 230 | 0.020 |
Why?
|
Laryngoscopy | 1 | 2016 | 714 | 0.020 |
Why?
|
Pyrazoles | 1 | 2020 | 2028 | 0.020 |
Why?
|
Jugular Veins | 1 | 1991 | 211 | 0.020 |
Why?
|
Acyclovir | 1 | 1991 | 267 | 0.020 |
Why?
|
Data Collection | 1 | 1999 | 3326 | 0.020 |
Why?
|
Antibodies | 2 | 2015 | 2421 | 0.020 |
Why?
|
Base Sequence | 2 | 1992 | 12422 | 0.020 |
Why?
|
Receptor, TIE-2 | 1 | 2010 | 183 | 0.020 |
Why?
|
Activities of Daily Living | 1 | 2019 | 2430 | 0.020 |
Why?
|
Vidarabine | 1 | 1991 | 337 | 0.020 |
Why?
|
Opportunistic Infections | 1 | 2012 | 375 | 0.020 |
Why?
|
Infant | 4 | 2015 | 36535 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2000 | 8142 | 0.020 |
Why?
|
Cell Growth Processes | 1 | 2010 | 381 | 0.020 |
Why?
|
Corpus Callosum | 1 | 2014 | 752 | 0.020 |
Why?
|
Mice, Knockout | 2 | 2019 | 14488 | 0.020 |
Why?
|
Qualitative Research | 1 | 2020 | 3140 | 0.020 |
Why?
|
Prednisone | 1 | 2014 | 1567 | 0.020 |
Why?
|
Fibroblasts | 2 | 2009 | 4178 | 0.020 |
Why?
|
Cells, Cultured | 3 | 2009 | 19025 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 2015 | 15662 | 0.020 |
Why?
|
Enterovirus Infections | 1 | 1989 | 74 | 0.020 |
Why?
|
Prevalence | 2 | 2011 | 15869 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2011 | 592 | 0.020 |
Why?
|
Cerebellum | 1 | 1996 | 1522 | 0.020 |
Why?
|
Cell Movement | 1 | 2020 | 5213 | 0.020 |
Why?
|
Microscopy, Electron | 1 | 2012 | 2560 | 0.020 |
Why?
|
Sulfonamides | 1 | 2018 | 1982 | 0.020 |
Why?
|
Guinea Pigs | 1 | 1990 | 1309 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2022 | 26379 | 0.020 |
Why?
|
Molecular Sequence Data | 2 | 1992 | 17623 | 0.020 |
Why?
|
Cell Survival | 1 | 2018 | 5789 | 0.020 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 1990 | 781 | 0.020 |
Why?
|
Chick Embryo | 1 | 1990 | 975 | 0.020 |
Why?
|
Cyclophosphamide | 1 | 2014 | 2227 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2013 | 2862 | 0.020 |
Why?
|
DNA Damage | 1 | 2018 | 2469 | 0.020 |
Why?
|
Gene Expression Regulation, Viral | 1 | 1990 | 435 | 0.020 |
Why?
|
Catenins | 1 | 2007 | 44 | 0.020 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 1990 | 1730 | 0.020 |
Why?
|
Standard of Care | 1 | 2011 | 568 | 0.020 |
Why?
|
Health Personnel | 1 | 2021 | 3384 | 0.020 |
Why?
|
Bromodeoxyuridine | 1 | 2007 | 310 | 0.020 |
Why?
|
Radiography, Thoracic | 1 | 2014 | 1321 | 0.020 |
Why?
|
Doxorubicin | 1 | 2014 | 2234 | 0.020 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2014 | 1942 | 0.020 |
Why?
|
Nervous System Diseases | 1 | 2017 | 1662 | 0.020 |
Why?
|
Incidental Findings | 1 | 2011 | 698 | 0.020 |
Why?
|
Plasmids | 1 | 1992 | 2269 | 0.020 |
Why?
|
Quality Improvement | 1 | 2022 | 3857 | 0.020 |
Why?
|
Drug Delivery Systems | 1 | 1998 | 2237 | 0.020 |
Why?
|
Gene Expression | 1 | 2019 | 7601 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2023 | 10266 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2017 | 13422 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 1999 | 3269 | 0.020 |
Why?
|
Antibody Formation | 1 | 1990 | 1393 | 0.020 |
Why?
|
Contrast Media | 1 | 2018 | 5330 | 0.020 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2009 | 681 | 0.020 |
Why?
|
Chemokines, CXC | 1 | 2007 | 420 | 0.020 |
Why?
|
Coronary Aneurysm | 1 | 2007 | 234 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 1996 | 5505 | 0.020 |
Why?
|
Chemokine CXCL12 | 1 | 2007 | 457 | 0.010 |
Why?
|
Rats | 1 | 2000 | 23782 | 0.010 |
Why?
|
Computer Simulation | 1 | 2017 | 6283 | 0.010 |
Why?
|
Kinetics | 1 | 1992 | 6330 | 0.010 |
Why?
|
Patient-Centered Care | 1 | 2014 | 1444 | 0.010 |
Why?
|
Immunity, Cellular | 1 | 1990 | 1561 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 1996 | 4568 | 0.010 |
Why?
|
Students, Medical | 1 | 1997 | 1964 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2017 | 7852 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2015 | 3670 | 0.010 |
Why?
|
Hyperlipidemias | 1 | 2007 | 772 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2020 | 11930 | 0.010 |
Why?
|
Genetic Vectors | 1 | 1992 | 3403 | 0.010 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2013 | 2909 | 0.010 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2012 | 6029 | 0.010 |
Why?
|
Cytoskeleton | 1 | 2007 | 1179 | 0.010 |
Why?
|
Apoptosis | 1 | 2018 | 9527 | 0.010 |
Why?
|
Virus Replication | 1 | 1990 | 2458 | 0.010 |
Why?
|
Membrane Proteins | 2 | 2010 | 7876 | 0.010 |
Why?
|
Patient Preference | 1 | 2009 | 946 | 0.010 |
Why?
|
Lymphocytes | 1 | 1990 | 2614 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 2012 | 4913 | 0.010 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2009 | 997 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2013 | 5797 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2014 | 4206 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 1990 | 6231 | 0.010 |
Why?
|
Antibodies, Bacterial | 1 | 2007 | 1478 | 0.010 |
Why?
|
Cell Cycle | 1 | 2009 | 2934 | 0.010 |
Why?
|
Databases, Factual | 1 | 2016 | 8080 | 0.010 |
Why?
|
Fibroblast Growth Factors | 1 | 2007 | 873 | 0.010 |
Why?
|
Anticonvulsants | 1 | 2010 | 1923 | 0.010 |
Why?
|
Bacteria | 1 | 1991 | 2216 | 0.010 |
Why?
|
Registries | 1 | 2016 | 8375 | 0.010 |
Why?
|
Cognition Disorders | 1 | 2014 | 3980 | 0.010 |
Why?
|
Actins | 1 | 2007 | 2064 | 0.010 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2007 | 952 | 0.010 |
Why?
|
Cerebral Cortex | 1 | 1996 | 5812 | 0.010 |
Why?
|
Disease Outbreaks | 1 | 1989 | 1761 | 0.010 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2009 | 2885 | 0.010 |
Why?
|
Thrombocytopenia | 1 | 2007 | 1179 | 0.010 |
Why?
|
Neoplastic Stem Cells | 1 | 2007 | 1351 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 2013 | 5804 | 0.010 |
Why?
|
Survival Analysis | 2 | 2007 | 10099 | 0.010 |
Why?
|
Lumbar Vertebrae | 1 | 2007 | 1886 | 0.010 |
Why?
|
Encephalitis | 2 | 1991 | 441 | 0.010 |
Why?
|
Comorbidity | 1 | 2011 | 10590 | 0.010 |
Why?
|
Decision Making | 1 | 2009 | 3953 | 0.010 |
Why?
|
Cell Line | 1 | 2009 | 15602 | 0.010 |
Why?
|
Echocardiography | 1 | 2007 | 5047 | 0.010 |
Why?
|
Medically Underserved Area | 1 | 1997 | 268 | 0.010 |
Why?
|
Palliative Care | 1 | 2009 | 3643 | 0.010 |
Why?
|
Proteins | 1 | 2009 | 6009 | 0.010 |
Why?
|
Endothelial Cells | 1 | 2007 | 3589 | 0.010 |
Why?
|
B-Lymphocytes | 1 | 2007 | 4793 | 0.010 |
Why?
|
Solubility | 1 | 1995 | 1086 | 0.010 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 1995 | 348 | 0.010 |
Why?
|
Permeability | 1 | 1995 | 726 | 0.010 |
Why?
|
Serum Albumin | 1 | 1995 | 677 | 0.010 |
Why?
|
Dihydroxyphenylalanine | 1 | 1971 | 74 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2010 | 16044 | 0.010 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 1991 | 187 | 0.010 |
Why?
|
Philadelphia | 1 | 1989 | 271 | 0.000 |
Why?
|
Neurologic Examination | 1 | 1989 | 914 | 0.000 |
Why?
|
Serotonin | 1 | 1971 | 1043 | 0.000 |
Why?
|
Consciousness | 1 | 1991 | 602 | 0.000 |
Why?
|
Vaccination | 1 | 1997 | 3437 | 0.000 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 1995 | 4355 | 0.000 |
Why?
|
Spinal Cord | 1 | 1989 | 1812 | 0.000 |
Why?
|
Recurrence | 1 | 1991 | 8509 | 0.000 |
Why?
|
Multivariate Analysis | 1 | 1991 | 12077 | 0.000 |
Why?
|
Hydroxyindoleacetic Acid | 1 | 1971 | 94 | 0.000 |
Why?
|
Blood Cell Count | 1 | 1971 | 406 | 0.000 |
Why?
|
Follicle Stimulating Hormone | 1 | 1971 | 727 | 0.000 |
Why?
|
Luteinizing Hormone | 1 | 1971 | 822 | 0.000 |
Why?
|
Sleep, REM | 1 | 1971 | 595 | 0.000 |
Why?
|
Placebos | 1 | 1971 | 1667 | 0.000 |
Why?
|
Motor Activity | 1 | 1971 | 2711 | 0.000 |
Why?
|
Blood Platelets | 1 | 1971 | 2479 | 0.000 |
Why?
|